Welcome to our dedicated page for Wellgistics Health SEC filings (Ticker: WGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how a niche pharmaceutical distributor like Wellgistics Health Inc. (WGRX) navigates FDA regulations, temperature-controlled logistics, and reimbursement rules isn’t easy. Each 10-K packs dense disclosures about specialty-drug margins, while every 8-K details new wholesaler contracts that can reshape revenue overnight. If you have ever wondered, “Why are Wellgistics Health insider trading Form 4 transactions spiking before a new supplier deal?” you are not alone.
Stock Titan solves the puzzle. Our AI reads every Wellgistics Health quarterly earnings report 10-Q filing the moment it hits EDGAR, then delivers plain-English highlights—cash-flow swings, inventory turns, and segment performance—so you can focus on decisions, not decoding. Need real-time alerts? We ping you the second a Wellgistics Health Form 4 insider transactions real-time notice appears. The platform also answers natural questions such as “Are Wellgistics Health SEC filings explained simply anywhere?” or “What does today’s 8-K mean for cold-chain capacity?”
Beyond summaries, you’ll find deep links to every document type investors care about:
- 10-K & 10-Q: Examine logistics network costs with our Wellgistics Health earnings report filing analysis and Wellgistics Health annual report 10-K simplified.
- Forms 4: Track Wellgistics Health executive stock transactions Form 4 to spot confidence shifts.
- DEF 14A: See the Wellgistics Health proxy statement executive compensation breakdown of distribution-team incentives.
- 8-K: Get Wellgistics Health 8-K material events explained—from new warehouse leases to supply interruptions.
Wellgistics Health, Inc. (WGRX) is offering 7,142,862 shares of Common Stock at $0.70 per share, producing approximately $4,650,003 of proceeds before expenses with placement agent fees of $350,000. After the offering and assuming no warrants are exercised, the company expects 91,406,962 shares outstanding. The filing discloses a consolidated net loss of $39,103,367 for a reported period, with weighted average common shares of 56,863,720 and a net loss per share of $0.63 in one table. Pro forma and segment tables show other reported net losses (for example, $10,592,215 and $6,856,226 in separate schedules). The company reports an actual net tangible book value per share before the offering of $(0.47) and an offering price of $0.70, but the filing leaves some post-offering per-share calculations blank. The company completed the Wellgistics acquisition with cash consideration terms including a $10 million closing payment and issuance of a $17,500,000 note payable (amended terms), plus issuance of 3,999,335 restricted shares valued at $15,000,000 as equity consideration. A U.S. utility patent application titled "Method and Apparatus for Prescription Management" was filed July 26, 2022 and submitted September 26, 2023 to protect the company’s tech and hub platform.
Wellgistics Health, Inc. is amending its S-1 registration to offer up to 5,357,142 shares of Common Stock at an assumed public offering price of $1.40 per share. After the offering (and assuming full exercise of any Pre-Funded Warrants and no exercise of accompanying Warrants) the company would have 89,621,242 shares outstanding. The filing discloses a recent acquisition (Wellgistics) with pro forma recognition of substantial goodwill and intangible assets and transaction consideration that included a cash component and issuance of 3,999,335 restricted shares valued at $15,000,000.
The company reported consolidated losses in the periods presented, including a combined net loss of $39,103,367 (weighted average shares 56,863,720, net loss per share $0.69) and other historical net losses (for a prior period of $10,592,215). The pro forma balance sheet includes a note payable originally $15,000,000 that was amended to a principal of $17,500,000 payable in installments. The filing also discloses a U.S. utility patent application titled "Method and Apparatus for Prescription Management."
Wellgistics Health, Inc. (WGRX) files an amended S-1 registration describing its proposed public offering, recent acquisition accounting, capital structure and historical results. The company discloses a consolidated net loss of $39,103,367 and a weighted average of 56,863,720 common shares, implying a reported net loss per share of $0.63 in the presented period. The pro forma capital table reflects the issuance and sale of 11,182,565 shares subsequent to June 30, 2025 and potential additional shares or pre-funded warrants in the offering.
The filing explains material transaction terms: a patent application titled “Method and Apparatus for Prescription Management” (filed July 26, 2022; submitted Sep 26, 2023), issuance of 3,999,335 restricted shares valued at $15,000,000 as acquisition consideration, and a note payable originally $15,000,000 that was amended to a principal of $17,500,000 with scheduled installments in 2026 and 2028. The company reports a net tangible book value per share before the offering of $(0.60) and names Colonial Stock Transfer Company as transfer agent. Major insider holdings disclosed include Brian Norton (10,990,247 shares; 13.04%) and Suren Ajjarapu (10,445,447 shares; 12.40%).
Wellgistics Health, Inc. files an amended S-1 showing a combined set of operations and pro forma adjustments tied to the acquisition of Wellgistics. The company reported a consolidated net loss of $39,103,367 in one presented period with a weighted average of 56,863,720 shares and reported net loss per share figures of $0.63 and $0.69 in related tables. The filing discloses an offering of common stock (shares unspecified in this excerpt) at an assumed public price tied to the Nasdaq closing price on a 2025 date and shows outstanding common shares of 72,881,535 issued and 63,144,817 outstanding as of June 30, 2025.
The company details material transaction terms from the Wellgistics acquisition including a $15,000,000 note payable due in three equal annual installments beginning February 14, 2026, and issuance of 3,999,335 restricted shares recognized at a fair value of $15,000,000 as equity consideration. A U.S. utility patent application titled “Method and Apparatus for Prescription Management” was filed (July 26, 2022; submitted Sept 26, 2023) covering the tech and hub platform. Financial tables show material operating losses, high general and administrative expenses, and pro forma adjustments to goodwill and intangible assets.
Wellgistics Health, Inc. reported significant operating losses and liquidity strain for the period ending June 30, 2025. The company recorded a net loss of $39.1 million for the six months and $6.67 million for the three months, contributing to an accumulated deficit of $48.86 million. Net cash used in operating activities for the six months was $3.43 million, and the registrant disclosed that these factors raise substantial doubt about its ability to continue as a going concern. The company completed an IPO raising gross proceeds of $4.0 million (net approx. $3.1 million) and issued shares under an equity purchase agreement that was subsequently terminated on August 13, 2025. Debt and credit facilities remain significant, including a revolving line of credit balance of $3.98 million and seller notes with $5.0 million classified as current. Intangible assets and goodwill are material on the balance sheet (~$19.2 million and $16.2 million, respectively). The filing also discloses a customer concentration risk (~15% of revenue) and elevated stock-based compensation and restricted-share programs.
FAQ
What is the current stock price of Wellgistics Health (WGRX)?
What is the market cap of Wellgistics Health (WGRX)?
